Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: Nov 13, 2024
Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints
Read more at globenewswire.com3.89
-0.14 (-3.47%)
Find more stocks in the Stock Screener
LXEO Latest News and Analysis
3 days ago - ChartmillStay updated with the stocks that are on the move in today's pre-market session.As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
